Role of Ketamine in the Treatment of Psychiatric Disorders
# Purpose of review This is a comprehensive review of the literature regarding the use of ketamine as a treatment for treatment-resistant depression (TRD). It covers the epidemiology, risk factors, pathophysiology, and current treatment modalities regarding Major Depressive Disorder (MDD) and TRD....
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2021-06-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.25091 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823857483750309888 |
|---|---|
| author | Sahar Derakhshanian Maxine Zhou Alexander Rath Rachel Barlow Sarah Bertrand Caroline DeGraw Christopher Lee Jamal Hasoon Alan D. Kaye |
| author_facet | Sahar Derakhshanian Maxine Zhou Alexander Rath Rachel Barlow Sarah Bertrand Caroline DeGraw Christopher Lee Jamal Hasoon Alan D. Kaye |
| author_sort | Sahar Derakhshanian |
| collection | DOAJ |
| description | # Purpose of review
This is a comprehensive review of the literature regarding the use of ketamine as a treatment for treatment-resistant depression (TRD). It covers the epidemiology, risk factors, pathophysiology, and current treatment modalities regarding Major Depressive Disorder (MDD) and TRD. It provides background on the mechanism of action of ketamine, its history, current approved and off-label indications in the field of psychiatry, and then provides an overview of the existing evidence for the use of ketamine in the treatment of TRD.
# Recent findings
MDD is a mental illness that puts an enormous strain on the affected and a high socio-economic burden on society. The illness is complex and combines genetic, pathophysiologic, and environmental factors that combine to negatively affect neurotransmitter balance in the brain. Additional evidence suggests dysregulation of the hypothalamic-pituitary (HPA) axis, brain-derived neurotrophic factor (BDNF), vitamin D levels, and involvement of pro-inflammatory markers. Core symptoms include depressed mood or anhedonia, combined with neurovegetative symptoms such as sleep impairment, changes in appetite, feelings of worthlessness and guilt, and psychomotor retardation. Current first-line treatment options are antidepressants of the selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) class. Failure to respond to two adequate trials of treatment meets the criteria for TRD. Esketamine (Spravato) is an NMDA-receptor antagonist with additional AMPA-receptor agonist properties, which the FDA approved in 2019 to treat adult TRD in conjunction with an oral antidepressant. It can be administered intranasally, providing a rapid response and proven effective and safe. Additional research suggests that oral ketamine might be effective for PTSD and anxiety disorders. Intravenous administration of ketamine has also shown benefits for acute suicidal ideation and depression and substance use to reduce relapse rates.
# Summary
TRD is associated with huge costs on individual and societal levels. Underlying disease processes are multifactorial and not well understood. Adjunctive therapies for TRD with proven benefits exist, but acutely depressed and suicidal patients often require prolonged inpatient stabilization. Intranasal esketamine is a new FDA-approved alternative with rapid benefit for TRD, which has also shown a rapid reduction in suicidal ideation while maintaining a favorable side-effect profile. Additional potential off-label uses for ketamine in psychiatric disorders have been studied, including PTSD, anxiety disorders, bipolar depression, and substance use disorders. |
| format | Article |
| id | doaj-art-3e7b393449d44ff0b945115c436bed97 |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-3e7b393449d44ff0b945115c436bed972025-02-11T20:30:34ZengOpen Medical PublishingHealth Psychology Research2420-81242021-06-0191Role of Ketamine in the Treatment of Psychiatric DisordersSahar DerakhshanianMaxine ZhouAlexander RathRachel BarlowSarah BertrandCaroline DeGrawChristopher LeeJamal HasoonAlan D. Kaye# Purpose of review This is a comprehensive review of the literature regarding the use of ketamine as a treatment for treatment-resistant depression (TRD). It covers the epidemiology, risk factors, pathophysiology, and current treatment modalities regarding Major Depressive Disorder (MDD) and TRD. It provides background on the mechanism of action of ketamine, its history, current approved and off-label indications in the field of psychiatry, and then provides an overview of the existing evidence for the use of ketamine in the treatment of TRD. # Recent findings MDD is a mental illness that puts an enormous strain on the affected and a high socio-economic burden on society. The illness is complex and combines genetic, pathophysiologic, and environmental factors that combine to negatively affect neurotransmitter balance in the brain. Additional evidence suggests dysregulation of the hypothalamic-pituitary (HPA) axis, brain-derived neurotrophic factor (BDNF), vitamin D levels, and involvement of pro-inflammatory markers. Core symptoms include depressed mood or anhedonia, combined with neurovegetative symptoms such as sleep impairment, changes in appetite, feelings of worthlessness and guilt, and psychomotor retardation. Current first-line treatment options are antidepressants of the selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) class. Failure to respond to two adequate trials of treatment meets the criteria for TRD. Esketamine (Spravato) is an NMDA-receptor antagonist with additional AMPA-receptor agonist properties, which the FDA approved in 2019 to treat adult TRD in conjunction with an oral antidepressant. It can be administered intranasally, providing a rapid response and proven effective and safe. Additional research suggests that oral ketamine might be effective for PTSD and anxiety disorders. Intravenous administration of ketamine has also shown benefits for acute suicidal ideation and depression and substance use to reduce relapse rates. # Summary TRD is associated with huge costs on individual and societal levels. Underlying disease processes are multifactorial and not well understood. Adjunctive therapies for TRD with proven benefits exist, but acutely depressed and suicidal patients often require prolonged inpatient stabilization. Intranasal esketamine is a new FDA-approved alternative with rapid benefit for TRD, which has also shown a rapid reduction in suicidal ideation while maintaining a favorable side-effect profile. Additional potential off-label uses for ketamine in psychiatric disorders have been studied, including PTSD, anxiety disorders, bipolar depression, and substance use disorders.https://doi.org/10.52965/001c.25091 |
| spellingShingle | Sahar Derakhshanian Maxine Zhou Alexander Rath Rachel Barlow Sarah Bertrand Caroline DeGraw Christopher Lee Jamal Hasoon Alan D. Kaye Role of Ketamine in the Treatment of Psychiatric Disorders Health Psychology Research |
| title | Role of Ketamine in the Treatment of Psychiatric Disorders |
| title_full | Role of Ketamine in the Treatment of Psychiatric Disorders |
| title_fullStr | Role of Ketamine in the Treatment of Psychiatric Disorders |
| title_full_unstemmed | Role of Ketamine in the Treatment of Psychiatric Disorders |
| title_short | Role of Ketamine in the Treatment of Psychiatric Disorders |
| title_sort | role of ketamine in the treatment of psychiatric disorders |
| url | https://doi.org/10.52965/001c.25091 |
| work_keys_str_mv | AT saharderakhshanian roleofketamineinthetreatmentofpsychiatricdisorders AT maxinezhou roleofketamineinthetreatmentofpsychiatricdisorders AT alexanderrath roleofketamineinthetreatmentofpsychiatricdisorders AT rachelbarlow roleofketamineinthetreatmentofpsychiatricdisorders AT sarahbertrand roleofketamineinthetreatmentofpsychiatricdisorders AT carolinedegraw roleofketamineinthetreatmentofpsychiatricdisorders AT christopherlee roleofketamineinthetreatmentofpsychiatricdisorders AT jamalhasoon roleofketamineinthetreatmentofpsychiatricdisorders AT alandkaye roleofketamineinthetreatmentofpsychiatricdisorders |